Vanguard Global Advisers
CRVS icon

Vanguard Global Advisers’s Corvus Pharmaceuticals CRVS Stock Holding History

Vanguard Global Advisers’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$712K Hold
47,688
– – ﹤0.01% 1942
2026
Q1 		$698K Buy
+47,688
New +$761K ﹤0.01% 1862

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Global Advisers's CRVS Position: Q2 2026 in Review

Vanguard Global Advisers held its Corvus Pharmaceuticals (CRVS) position steady in Q2 2026 at 47,688 shares worth $712K. The position accounts for ﹤0.01% of the portfolio, ranked #1942.

Vanguard Global Advisers first reported a position in CRVS in Q1 2026 and has held it in 2 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Vanguard Global Advisers held 47,688 shares of Corvus Pharmaceuticals worth $712K as of Q2 2026.
  • Vanguard Global Advisers left its Corvus Pharmaceuticals share count unchanged in Q2 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1942 holding.
  • Vanguard Global Advisers first reported a position in Corvus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.